You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021514020
Dec 202198011
Jan 20228607
Feb 202274010
Mar 202222805
Apr 20229606
May 2022104019
Jun 20227007
Jul 20221603
Aug 20228005
Sep 20223809
Oct 20229109
Nov 202258010
Dec 20224804
Jan 20232205
Feb 20233005
Mar 20232601
Apr 20233402
May 20231700
Jun 20234202
Jul 202322012
Aug 20231502
Sep 20231102
Oct 20232004
Nov 20233007
Dec 20235504
Jan 20243600
Feb 20245603
Mar 20245205
Apr 20241802
May 20243705
Jun 20241805
Jul 20242605
Aug 20242206
Total21900202